Alzheimer's drug lecanemab shows reduced cognitive decline in clinical trial
A monoclonal antibody drug, named lecanemab, has been tested in a Phase III clinical trial in nearly 1800 participants, with promising results in reducing the effects of Alzheimer's disease on the brain.
Eisai (Tokyo, Japan) and Biogen (MA, USA) have released the results from their Phase III clinical trial of lecanemab, showing that the drug can slow cognitive decline in patients suffering with Alzheimer’s disease.
Lecanemab is an investigational anti-amyloid beta protofibril antibody that is used to treat mild cognitive impairment that occurs due to Alzheimer’s disease and early Alzheimer’s disease with amyloid pathology in the brain.
The trial, conducted over 18 months, was a multicentre, double-blind trial including 1795 patients from 50–90 years of age with early Alzheimer’s disease with amyloid.
The efficacy of the drug was based on end points of a change in score on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) from baseline, and a change in amyloid burden as shown by positron-emission tomography (PET).
In the case of both end points, lecanemab appeared to reduce the amyloid burden in early Alzheimer’s disease and slowed decline in function and cognition according to the CDR-SB, compared to the placebo.
The results from the trial have been considered generally very positive, however, the researchers have stressed that application of lecanemab was associated with adverse events, and in 14% of the treatment group, severe adverse events. These reactions included infusion-related reactions, ARIA with microhaemorrhages, atrial fibrillation, syncope and angina. Deaths also occurred in 0.7% of the participants in the lecanemab group and 0.8% of the control group. The researchers highlight that the incidence of adverse events was similar between the test and control groups.
"All of these amyloid-lowering drugs carry a risk for increased brain haemorrhage," stated Ronald Petersen of the Mayo Clinic (MN, USA). "I think the primary outcomes, the secondary outcomes, the amyloid-lowering is pretty impressive."
The data presented in the paper, published in The New England Journal of Medicine, also showed that according to the CDR-SB, those who had a genetic disposition to developing early Alzheimer’s disease did not show significant improvements with lecanemab.
The companies have applied for accelerated approval for the drug from the US FDA, hoping to be able to conduct further long-term studies and start treating patients, stating that the earlier the drug can be used in the disease stage, the more impact it will have on slowing cognitive decline.
"I believe it's an important benefit that will justify full approval. But of course, we want a bigger benefit… before you've accumulated enough irreversible damage to be causing symptoms" commented Paul Aisen, Director of the University of Southern California Alzheimer’s Therapeutic Research Institute (CA, USA) and a co-author of the study.
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients.
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. This instalment highlights not only the importance of ma...
Joining the strong number of cancer therapies being approved in 2023 is the CAR-T cell therapy from Invectys, the clinical-stage immuno-oncology company.
In the most recent instalment of the CPHI Podcast Series, Digital Editor Lucy Chard is joined by Sandra Sánchez y Oldenhage, President and CEO of PharmAdvice, to discuss nearshoring and reshoring in the pharmaceutical industry, and the subs...
The pharmaceutical supply chain has encountered numerous disruptions in the last few years, impacting procurement, manufacturing, packaging, and distribution operations within the pharmaceutical industry. Read about the rise in calls for near/resh...
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Several biosimilars to AbbVie’s monoclonal antibody therapeutic Humira were launched by various pharmaceutical giants this week in the US, with more expected to be released by the end of the year as the patent expires.
In the USA, President Joe Biden will be signing an executive order to expand access to contraception.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
Your company’s profile boosted at all participating CPHI events
An easy-to-use platform with a detailed dashboard showing your leads and performance